Emergence Therapeutics

Emergence Therapeutics is a European biopharmaceutical company that focuses on developing cutting-edge antibody-drug conjugates (ADCs) to target high-priority cancers, including Nectin-4. The company's leading program involves combining optimized linker and payload technology with a highly specific antibody to effectively target Nectin-4, a key element in a wide variety of cancers. This effort is underpinned by the clinical success of enfortumab vedotin, a treatment approved by the US FDA for urothelial cancers, which validates the importance of Nectin-4 as a target. Founded in 2019 and headquartered in Germany, Emergence Therapeutics recently secured a significant €87.00M Series A investment on 07 December 2021. Notably, the investment came from a syndicate of influential backers including High-Tech Gründerfonds, Bpifrance, Kurma Partners, Pontifax, RA Capital Management, OrbiMed, Gruenderfonds Ruhr, Hadean Partners, NRW BANK, and Surveyor Capital. With a strong focus on addressing unmet therapeutic needs, Emergence Therapeutics positions itself as a significant player in the Biotechnology and Health Care industries, offering promising potential for patient care and investment opportunities.